On this page
Our prior position — and why it was incomplete
Melatonin entered our database in early 2024. At the time, our scoring was weighted heavily toward dose accuracy and FSSAI compliance: does the label state the dose clearly, is the amount consistent with what's in the capsule, and is the product legitimately licensed. By those criteria, a 10mg tablet with honest labelling scored similarly to a 0.5mg tablet with honest labelling. We treated dose size as a consumer choice, not a formulation error.
That was wrong. The five papers below, read in sequence over the course of a single Saturday, changed our position. We now score high-dose melatonin products down on the clinical dose dimension specifically — not because large doses are dangerous, but because the evidence indicates they are pharmacologically counterproductive for the primary use case: sleep onset and circadian phase adjustment. The score rubric reflects this.
Dose size was scored on accuracy, not appropriateness. A 10mg product with correct labelling scored 8+/10 on dose. We treated higher as "more conservative margin."
Dose size is now scored against the physiological range (0.3–1mg). Products above 3mg lose points on clinical dose — the evidence does not support pharmacological dosing for sleep-onset use cases.
Reading list posts are not comprehensive literature reviews. They are honest accounts of what we actually read, in what order, and what each paper moved. Five papers follow. Evidence tier is stated for each.
The five papers
Dose-response relationships for resetting of human circadian clock by light
This is the foundational dose-response paper. Lewy's group at OHSU were studying melatonin as a chronobiotic — a compound that shifts the timing of the body clock — rather than as a sedative. They found that the circadian system responds to melatonin at concentrations that closely mimic the natural nocturnal peak: roughly 100–200pg/mL in plasma, achievable with 0.3–0.5mg oral supplementation.
What the paper established — and what subsequent work confirmed — is that the MT1 and MT2 receptors in the suprachiasmatic nucleus (the circadian pacemaker in the hypothalamus) are not dose-linear above this threshold. Saturating these receptors with pharmacological doses produces no additional phase-shifting. The extra melatonin circulates, extends the half-life of elevated plasma melatonin into morning hours, and contributes to next-day sedation that consumers often misread as evidence the product "worked." 1
This paper established that the mechanism of action — receptor saturation kinetics at the SCN — does not support high-dose use. We added "physiological dose range" as a explicit criterion in our dose scoring rubric for melatonin specifically.
Melatonin treatment for age-related insomnia
Zhdanova's trial is important because it directly compared 0.3mg against 3mg in the same population, with sleep architecture measured by polysomnography rather than self-report. Both doses reduced sleep onset latency. Only the 0.3mg dose produced plasma melatonin profiles that normalised by morning. The 3mg dose resulted in elevated melatonin persisting 8–10 hours post-administration — meaning participants woke with pharmacological melatonin levels still active. 2
The clinical implication is direct: the 3mg dose produced a pharmacological hangover that the 0.3mg dose did not. In a supplement context, this translates into next-day grogginess — the complaint that leads most Indian consumers to stop taking melatonin within 2–3 weeks of starting it, typically on a 5mg or 10mg product.
Our dose rubric previously set "accurate label claim" as the primary metric. This paper added a second axis: does the stated dose produce physiological or pharmacological plasma levels. Doses above 1mg now face a higher burden of justification in our scoring.
Effects of exogenous melatonin on sleep: a meta-analysis
This is the first of two systematic reviews in our list, and the most important for re-framing melatonin as a category. Brzezinski pooled 17 RCTs and found a consistent, modest improvement in sleep onset latency across the literature — approximately 7–12 minutes on average. The key finding for our purposes was the dose-response analysis: there was no statistically significant relationship between dose and effect size across trials. 3
The meta-analysis also separated primary insomnia from secondary and circadian endpoints. For circadian phase disruption (jet lag, shift work), the evidence was stronger and the dose-dependence was if anything inverse — lower doses performed as well as higher doses for phase-shifting. For primary insomnia, the effect size was modest regardless of dose.
| Use case | Effect size (Cohen's d) | Optimal dose (from evidence) | Indian shelf offers |
|---|---|---|---|
| Circadian phase shift (jet lag, shift work) | Moderate–strong (0.6–0.9) | 0.5–1mg, timed to destination night | 5–10mg, no timing guidance |
| Sleep onset latency (primary insomnia) | Small–moderate (0.2–0.4) | 0.3–1mg, 30–60 min pre-bed | 5–10mg, no dose rationale |
| Total sleep time | Small (0.1–0.2) | Weak evidence at any dose | Often implied on label |
Melatonin's effect size for primary insomnia is modest across the literature — a fact we were not emphasising clearly enough in our reviews. We revised our ingredient page to lead with "chronobiotic" rather than "sleep supplement" and added explicit effect size context.
Efficacy and safety of exogenous melatonin for secondary sleep disorders — systematic review
The BMJ paper is methodologically rigorous — it applied Cochrane criteria to the literature and was explicit about evidence quality in a way that earlier narrative reviews were not. The conclusion that melatonin is primarily a chronobiotic rather than a general sedative was uncomfortable for the supplement industry, and this paper was poorly received by companies selling melatonin for "sleep support" broadly. 4
The safety data in Buscemi was the other significant contribution. They found no serious adverse events in the short-term literature, but noted a consistent pattern of next-day sedation and headache at doses above 3mg — the same phenomenon Zhdanova had observed pharmacokinetically. The two papers together built a coherent picture: high doses work no better and feel worse.
We added "circadian endpoint specificity" as a label honesty criterion. Products that market melatonin for "deep sleep" or "sleep quality" without acknowledging its primary circadian mechanism now face a label honesty penalty in our rubric.
Optimal doses for melatonin supplementation therapy in older adults — a combined analysis
Vural's analysis fills in the pharmacokinetic picture that the clinical trials gestured at but didn't quantify precisely. Oral bioavailability of melatonin is low and highly variable (3–33%), with significant first-pass hepatic metabolism. A 0.5mg dose reliably produces plasma concentrations of 50–200pg/mL — within the physiological nocturnal range. A 10mg dose produces concentrations of 5,000–15,000pg/mL — 25–75 times higher than the physiological peak. 5
The elimination half-life of melatonin is approximately 40–60 minutes. A 10mg dose taken at 10pm produces detectable supraphysiological levels until 6–8am the following morning. This is not a theoretical concern — it is the pharmacokinetic explanation for why consumers on 10mg melatonin commonly report difficulty waking, morning grogginess, and what they describe as "feeling like I took too much." Because they did.
This paper anchored our dose scoring with actual pharmacokinetic numbers. We can now articulate exactly why 10mg is the wrong dose: it produces 25–75× the physiological peak and persists 8+ hours. The rubric deduction is now grounded in mechanism, not preference.
The Indian shelf — what is actually available
We checked Amazon.in, 1mg, and three Bengaluru pharmacy chains in March 2026 for melatonin products. The evidence-supported dose range is 0.3–1mg. Here is what the shelf offers:
"Four of the six products we found are dosing at 10–33 times the physiologically active range. This is not a minor calibration issue — it is a category-wide mismatch between what the literature supports and what the shelf sells."
The short rant about 10mg gummies
Why 10mg became the default — and why it's a commercial accident, not a clinical one
The 10mg dose became prevalent in India by import and imitation, not by design. Early US melatonin products in the 1990s were sold in 3mg tablets — already high by physiological standards — because they were cheaper to manufacture at scale in that format. Indian brands copied the US shelf without reviewing the literature that had already, by 2005, established the dose problem. The gummy format compounded this: a gummy requires a minimum dose to be palatable, and 1mg gummies are technically harder to formulate than 5mg or 10mg. So the gummy format structurally favours high doses, and the Indian gummy sleep supplement market has converged almost entirely on 5–10mg. None of this is supported by any evidence of clinical benefit over 0.3–1mg. It is a manufacturing and marketing accident that has become a category norm.
We are not calling for a regulatory ban on high-dose melatonin — the safety profile at these doses is acceptable for short-term use. What we are saying is that any supplement brand that sells 10mg melatonin and markets it as a "clinically dosed sleep supplement" has not read the five papers above. If they have read them and are still selling 10mg, they have decided that the dose that sells is more important than the dose that the evidence supports. Neither is a compliment.
Our current recommendation, updated following this reading list: 0.3–1mg, taken 30–60 minutes before your intended sleep time, not your habitual sleep time. If you are using it for jet lag, timing relative to destination night matters more than dose. The Wellbeing Nutrition Calm (0.5mg) and imported NOW Foods (1mg) are currently the only products on Amazon.in we'd point someone toward without qualification on dose.
Full references
-
[1]
Lewy AJ, Ahmed S, Jackson JML, Sack RL (1992). Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiology International, 9(5):380–392. doi →
-
[2]
Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU (2001). Melatonin treatment for age-related insomnia. Journal of Clinical Endocrinology & Metabolism, 86(10):4727–4730. doi →
-
[3]
Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005). Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews, 9(1):41–50. doi →
-
[4]
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction. BMJ, 332(7538):385–393. doi →
-
[5]
Vural EM, van Munster BC, de Rooij SE (2014). Optimal doses for melatonin supplementation therapy in older adults: a combined analysis of current studies. Drugs & Aging, 31(6):441–451. doi →
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy